Latent tuberculosis detection by interferon γ release assay during pregnancy predicts active tuberculosis and mortality in human immunodeficiency virus type 1-infected women and their children

Journal of Infectious Diseases

Volumn 202, Issue 12, 2010, Pages 1826-1835

  Jonnalagadda, Sasi ^a   Payne, Barbara Lohman ^a   Brown, Elizabeth ^a   Wamalwa, Dalton ^b   Obimbo, Elizabeth Maleche ^b   Majiwa, Maxwel ^a   Farquhar, Carey ^a   Otieno, Phelgona ^c   Mbori Ngacha, Dorothy ^b   John Stewart, Grace ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ADULT; ARTICLE; ASSAY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INTERFERON PRODUCTION; KENYA; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MATERNAL MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INTERFERON-GAMMA; KENYA; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; PROGNOSIS; YOUNG ADULT;

EID: 78650399617     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/657411     Document Type: Article

References (38)

1. Mofenson LM, Laughon BE. Human immunodeficiency virus, Mycobacterium tuberculosis, and pregnancy: a deadly combination. Clin Infect Dis 2007; 45(2):250-253.
2. Khan M, Pillay T, Moodley J, Connolly C. Maternal mortality associated with tuberculosis-HIV-1 co-infection in Durban, South Africa. AIDS 2001; 15:1857-1863.
3. Black V, Brooke S, Chersich MF. Effect of human immunodeficiency virus treatment on maternal mortality at a tertiary center in South Africa: a 5-year audit. Obstet Gynecol 2009; 114(2 pt 1):292-299.
4. Holmes CB, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis 1998; 2(2):96-104.
5. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99(2):131-138.
6. Fine PE, Bruce J, Ponnighaus JM, Nkhosa P, Harawa A, Vynnycky E. Tuberculin sensitivity: conversions and reversions in a rural African population. Int J Tuberc Lung Dis 1999; 3(11):962-975.
7. Menzies D. Interpretation of repeated tuberculin tests: boosting, conversion, and reversion. Am J Respir Crit Care Med 1999; 159(1):15-21.
8. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350(20):2060-2067.
9. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146(5):340-354.
10. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149(3):177-184.
11. Lalvani A, Millington KA. T cell-based diagnosis of childhood tuberculosis infection. Curr Opin Infect Dis 2007; 20(3):264-271.
12. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-γ assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177(10):1164-1170.
13. Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T-cellbased, interferon-γ biomarker in children with tuberculosis contact. Ann Intern Med 2008; 149(11):777-787.
14. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-γ release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48(7):954-962.
15. Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 2008; 3(1):e1379.
16. Kik SV, Franken WP, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010; 35(6):1346-1353.
17. Otieno PA, Brown ER, Mbori-Ngacha DA, et al. HIV-1 disease progression in breast-feeding and formula-feeding mothers: a prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, and mortality. J Infect Dis 2007; 195(2):220-229.
18. Walson JL, Brown ER, Otieno PA, et al. Morbidity among HIV-1-infected mothers in Kenya: prevalence and correlates of illness during 2-year postpartum follow-up. J Acquir Immune Defic Syndr 2007; 46(2):208-215.
19. Panteleeff DD, John G, Nduati R, et al. Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. J Clin Microbiol 1999; 37(2):350-353.
20. Emery S, Bodrug S, Richardson BA, et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J ClinMicrobiol 2000; 38(7):2688-2695.
21. Division of Leprosy TaLD, Ministry of Public Health and Sanitation, Kenya. National NLTP guideline: what the health care worker needs to know. Ministry of Public Health and Sanitation Division of Leprosy, Tuberculosis and Lung Disease Web site. http://www.nltp.co.ke/docs/National-NLTP-Guideline.pdf. Published August 2005. Accessed 6 April 2010.
22. Kiarie JN, Richardson BA, Mbori-Ngacha D, Nduati RW, John-Stewart GC. Infant feeding practices of women in a perinatal HIV-1 pre vention study in Nairobi, Kenya. J Acquir Immune Defic Syndr 2004; 35(1):75-81.
23. Gupta A, Nayak U, Ram M, et al. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005. Clin Infect Dis 2007; 45(2):241-249.
24. Nachega J, Coetzee J, Adendorff T, et al. Tuberculosis active casefinding in a mother-to-child HIV transmission prevention programme in Soweto, South Africa. AIDS 2003; 17(9):1398-1400.
25. Leidl L, Mayanja-Kizza H, Sotgiu G, et al. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV-infection. Eur Respir J 2010; 35(3):619-626.
26. Talati NJ, Seybold U, Humphrey B, et al. Poor concordance between interferon-γ release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis 2009; 9:15.
27. Stephan C, Wolf T, Goetsch U, et al. Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIVinfected individuals from a low prevalence tuberculosis country. AIDS 2008; 22(18):2471-2479.
28. World Health Organization. Global tuberculosis control: a short update to the 2009 report. Geneva, Switzerland: World Health Organization, 2009.
29. Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367(9514):926-937.
30. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. J Immunol 1996; 157(3):1271-1278.
31. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364(9441):1236-1243.
32. Beffa P, Zellweger A, Janssens JP, Wrighton-Smith P, Zellweger JP. Indeterminate test results of T-SPOT.TB performed under routine field conditions. Eur Respir J 2008; 31(4):842-846.
33. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009; 136(1):198-204.
34. Mandalakas AM, Hesseling AC, Chegou NN, et al. High level of discordant IGRA results in HIV-infected adults and children. Int J Tuberc Lung Dis 2008; 12(4):417-423.
35. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis 2005; 24(8):529-536.
36. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001; 8(5):871-879.
37. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 2003; 187(2):226-242.
38. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004; (1):CD000171.